The stock of Heron Therapeutics Inc (NASDAQ:HRTX) hit a new 52-week low and has $13.79 target or 9.00% below today’s $15.15 share price. The 8 months bearish chart indicates high risk for the $598.91 million company. The 1-year low was reported on Oct, 17 by Barchart.com. If the $13.79 price target is reached, the company will be worth $53.90 million less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 246,162 shares traded hands. Heron Therapeutics Inc (NASDAQ:HRTX) has declined 18.87% since March 14, 2016 and is downtrending. It has underperformed by 24.48% the S&P500.
Analysts await Heron Therapeutics Inc (NASDAQ:HRTX) to report earnings on November, 4. They expect $-1.11 EPS, down 76.19% or $0.48 from last year’s $-0.63 per share. After $-1.17 actual EPS reported by Heron Therapeutics Inc for the previous quarter, Wall Street now forecasts -5.13% EPS growth.
Heron Therapeutics Inc (NASDAQ:HRTX) Ratings Coverage
Out of 6 analysts covering Heron Therapeutics (NASDAQ:HRTX), 6 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Heron Therapeutics has been the topic of 10 analyst reports since August 3, 2015 according to StockzIntelligence Inc. As per Wednesday, September 23, the company rating was maintained by Leerink Swann. Brean Capital maintained the shares of HRTX in a report on Monday, August 3 with “Buy” rating. Jefferies maintained it with “Buy” rating and $58 target price in Wednesday, September 23 report. The company was maintained on Monday, August 10 by Brean Capital. The stock of Heron Therapeutics Inc (NASDAQ:HRTX) earned “Buy” rating by Bank of America on Wednesday, September 2. As per Thursday, December 10, the company rating was initiated by Lake Street.
According to Zacks Investment Research, “Heron Therapeutics Inc. is a specialty pharmaceutical company. The company is developing products using its proprietary Biochronomer (TM) polymer-based drug delivery platform. Its product portfolio includes APF530, is being developed for the prevention of acute chemotherapy-induced nausea and vomiting. Heron Therapeutics Inc., formerly known as A.P. Pharma, Inc., is based in REDWOOD CITY CA.”
More recent Heron Therapeutics Inc (NASDAQ:HRTX) news were published by: Nasdaq.com which released: “Oversold Conditions For Heron Therapeutics” on October 03, 2016. Also Seekingalpha.com published the news titled: “Three execs out at Heron Therapeutics” on October 03, 2016. Seekingalpha.com‘s news article titled: “Heron Therapeutics Has An Upcoming Approval” with publication date: July 18, 2016 was also an interesting one.
HRTX Company Profile
Heron Therapeutics, Inc., incorporated on February 5, 1987, is a biotechnology company. The Firm is engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology (Biochronomer technology), which can deliver therapeutic levels of a range of otherwise short-acting pharmacological agents over a period of days to weeks with a single subcutaneous injection.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.